ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.

Conditions:   Multiple Myeloma in Relapse;   Multiple Myeloma Progression;   Multiple Myeloma Stage II;   Multiple Myeloma Stage I;   Multiple Myeloma With Failed Remission;   Multiple Myeloma Stage III Interventions:   Drug: Rivaroxaban;   Drug: ASA Sponsors:   Lawson Health Research Institute;   The Ottawa Hospital;   Dalhousie University;   St. Boniface General Hospital Research Centre;   McMaster University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials